Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins WHO approval for three HIV drugs

Ranbaxy says that the World Health Organisation has included the company's three HIV treatments in its pre-qualification list

India-based Ranbaxy has revealed that the World Health Organisation (WHO) has included the company's three HIV treatments in its pre-qualification list.

Ranbaxy says it now has 15 Anti Retroviral products (ARVs) in WHO's pre-qualification list, consisting of single and fixed dose combination products. The products are manufactured at the company's accredited sites in India.

The newly included ARVs are presented in compliance kit packs and are designed to enhance patient compliance for medication and are the latest additions to the WHO list.

The compliance packs contain two fixed dose combination tablets of lamivudine or zidovudine or Stavudine, with a single tablet of efavirenz. Of these, lamivudine or stavudine and efavirenz formulations are the first by any company on the WHO list, said Ranbaxy.

Ranbaxy has already filed a range of ARVs for FDA approval and has begun receiving tentative approvals from the US Federal agency under the President's Emergency Plan For AIDS Relief (PEPFAR) programme.

On 10 September, Ranbaxy's shares traded 1.3 per cent up at INR 415.30 on the Mumbai Stock Exchange.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics